1,134
Views
10
CrossRef citations to date
0
Altmetric
Original Articles: Prognosis, Prediction and Outcome

Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study

, , , ORCID Icon, , , , , , , ORCID Icon, , & show all
Pages 22-29 | Received 04 Jul 2021, Accepted 01 Oct 2021, Published online: 28 Oct 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jun Xu, Junying Song, Zhenhua Yang, Jianguo Zhao, Jianfang Wang, Caiping Sun & Xiaoling Zhu. (2023) Pre-treatment systemic immune-inflammation index as a non-invasive biomarker for predicting clinical outcomes in patients with renal cell carcinoma: a meta-analysis of 20 studies. Biomarkers 28:3, pages 249-262.
Read now

Articles from other publishers (9)

Lorenz Haaker, Marcella Baldewijns, Liesbeth De Wever, Maarten Albersen, Philip R. Debruyne, Wim Wynendaele, Gert De Meerleer & Benoit Beuselinck. (2023) Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis. Clinical Genitourinary Cancer.
Crossref
Se-Jun Park, Chang-Hyun Ma, Chong-Suh Lee, Chung-Youb Jeon, Tae-Soo Shin & Jin-Sung Park. (2022) Survival and Functional Outcomes after Surgical Treatment for Spinal Metastasis in Patients with a Short Life Expectancy. Journal of Clinical Medicine 12:1, pages 46.
Crossref
Yoshiaki Satou, Kousuke Ieiri, Takahito Negishi, Nobuki Furubayashi & Motonobu Nakamura. (2022) Change of genitourinary cancer patients’ perception and expectations over the course of pharmacotherapy. PLOS ONE 17:11, pages e0278039.
Crossref
Lauren E. Langbein, Rayan El Hajjar, William Y. Kim & Haifeng Yang. (2022) The convergence of tumor suppressors on the type I interferon pathway in clear cell renal cell carcinoma and its therapeutic implications. American Journal of Physiology-Cell Physiology 323:5, pages C1417-C1429.
Crossref
Wenxia Jiang, Yan Zhao, Suxia Zhang, Yu Zeng & Jun Ma. (2022) Aberrant expression of polo‑like kinase 4 in renal cell carcinoma: Association with clinicopathological characteristics and long‑term survival. Oncology Letters 24:6.
Crossref
Jessica E. Pritchard, Lauren E. Wilson, Samuel M. Miller, Melissa A. Greiner, Harvey Jay Cohen, Deborah R. Kaye, Tian Zhang & Michaela A. Dinan. (2022) Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. Journal of the American Geriatrics Society 70:8, pages 2330-2343.
Crossref
Eduard Roussel, Benoit Beuselinck & Maarten Albersen. (2022) Tailoring treatment in metastatic renal cell carcinoma. Nature Reviews Urology 19:8, pages 455-456.
Crossref
Eduard Roussel, Lisa Kinget, Annelies Verbiest, Jessica Zucman-Rossi, Bram Boeckx, Steven Joniau, Diether Lambrechts, Maarten Albersen & Benoit Beuselinck. (2022) Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma. European Urology Open Science 40, pages 54-57.
Crossref
Amir Ishaq Khan, Sarah P. Psutka, Dattatraya H. Patil, Gordon Hong, Milton A. Williams, Mehmet A. Bilen, Aarti Sekhar, Haydn T. Kissick, Vikram M. Narayan, Shreyas S. Joshi, Kenneth Ogan & Viraj A. Master. (2022) Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Cancer 128:11, pages 2073-2084.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.